SLC5A2 and diabetic kidney disease: Current therapeutic approaches for DKD primarily focus on the use of RAAS inhibitors and Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors, aimed at decelerating glomerular hyperfiltration and diminishing proteinuria (18).